Drug Database
CL

clopidogrel napadisilate (Pidogle / Pidogul)

✓ Approved

Hanmi Pharmaceutical · P2RY12 · 小分子

什么是 clopidogrel napadisilate?

clopidogrel napadisilate 是一种小分子,由Hanmi Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Pidogle, Pidogul
公司Hanmi Pharmaceutical
药物类别小分子
分子靶点P2RY12
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

clopidogrel napadisilate 作用于 1 个分子靶点:

P2RY12purinergic receptor P2Y12 (P2Y(ADP), P2Y(cyc))
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

clopidogrel napadisilate 针对 4 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersMyocardial infarction✓ Approved
Vascular disordersPeripheral vascular disorder✓ Approved
Cardiac disordersAcute coronary syndrome✓ Approved
Nervous system disordersDelayed ischaemic neurological deficit✓ Approved

相关研究文献

PubMedJournal of the American Heart Association2026-11-18

Rivaroxaban Inhibits Platelet-Driven NOX2-Dependent Oxidative Injury to Endothelium.

D'Amico Alessandra A, Picchio Vittorio V, Fabbi Patrizia P, Garibaldi Silvano S et al.

Endothelial dysfunction is a hallmark of cardiovascular disease, driven by oxidative stress, inflammation, and platelet activation. We hypothesized that the FXa inhibitor rivaroxaban, alone or combined with clopidogrel, could counteract platelet-induced oxidative injury to the endothelium and preserve endothelial function. We conducted a prospective multicenter cohort clinical study in patients on chronic antiplatelet therapy (mostly aspirin) who initiated rivaroxaban, measuring indices of oxidative stress, endothelial function (nitric oxide bioavailability, ICAM-1/VCAM-1 levels), and platelet activation before and after rivaroxaban. In parallel, human endothelial cells were exposed to convulxin-activated platelet supernatants from healthy donors with or without rivaroxaban±clopidogrel, and assessed for NOX2 expression/activity, adhesion molecules, nitric oxide (NO) production, and tube-forming capacity. An ex vivo mouse model of angiotensin II-induced endothelial dysfunction was used to evaluate vascular relaxation responses after incubation with rivaroxaban and/or clopidogrel. Rivaroxaban significantly improved endothelial function in patients and in vitro, as shown by reduced endothelial ICAM-1 and VCAM-1 expression and increased NO availability despite platelet-derived oxidative stress. Rivaroxaban also decreased H2O2 production, downregulated endothelial NOX2 expression and sNOX2-dp release, and restored angiogenic capacity in endothelial cells exposed to activated platelets. Clopidogrel alone had negligible effects on these parameters. Notably, adding clopidogrel to rivaroxaban provided no additional endothelial benefit beyond rivaroxaban monotherapy. In an ex vivo hypertensive vessel model, rivaroxaban (but not clopidogrel) markedly improved endothelium-dependent relaxation. Rivaroxaban effectively preserves endothelial function by inhibiting platelet-induced NOX2-mediated oxidative stress and inflammation. The lack of any additive benefit from clopidogrel suggests that rivaroxaban alone may be mechanistically sufficient to counteract platelet-driven endothelial dysfunction. These findings reveal a novel vasoprotective mechanism for rivaroxaban and underscore its potential clinical value in mitigating vascular injury beyond its established antithrombotic effects.

PMID 43048771
阅读全文 →
PubMedCureus2026-11-18

A Clinical Framework for Antithrombotic Review in Anticoagulated Patients With Stable Coronary Artery Disease: When Should Aspirin Be Stopped?

Sanjogita Fnu F, Qaiser Suleman S, Ali Muhammad M

Patients receiving oral anticoagulation (OAC) for atrial fibrillation frequently have concomitant coronary artery disease (CAD), raising questions about the duration of additional antiplatelet therapy. Triple antithrombotic therapy combines OAC with aspirin and a P2Y₁₂ inhibitor, usually clopidogrel, whereas dual antithrombotic therapy combines OAC with a single antiplatelet agent. Early aspirin withdrawal from triple therapy and subsequent withdrawal of the remaining antiplatelet are separate decisions requiring assessment of the coronary timeline and current treatment indications. This narrative editorial examines randomized evidence and proposes a structured medication review framework. The evidence generally supports OAC monotherapy in appropriately selected patients with stable CAD, with reduced bleeding and favourable net clinical outcomes compared with combined treatment. However, aspirin-specific findings require distinction from comparisons involving clopidogrel or mixed antiplatelet regimens. Overall trial results do not establish identical benefits or harms across patients with previous myocardial infarction, multivessel disease, or complex coronary intervention. Differences in eligibility and composite endpoints, geographic concentration, open-label designs, early termination in some trials, and limited precision for uncommon ischemic events constrain interpretation and generalizability. The proposed framework comprises verification of the OAC indication and regimen, establishment of the coronary timeline, assessment of any current antiplatelet indication, review of bleeding risks and drug interactions, and documentation of the decision, responsible clinician, and reassessment date. Extrapolation requires particular caution in patients with previous stent thrombosis, mechanical valves, or OAC prescribed for venous thromboembolism. Continued combination therapy requires a current, documented justification. The framework remains unvalidated, and its reproducibility, feasibility, and effects on prescribing, bleeding, and ischemic outcomes require prospective evaluation.

PMID 43047679
阅读全文 →
PubMedeNeurologicalSci2026-11-17

Comparison of clopidogrel versus prasugrel-based dual antiplatelet therapy in acute lacunar infarction: a single-center retrospective study.

Deguchi Ichiro I, Takahashi Shinichi S, Yokosuka Yu Y, Shoda Sotaro S et al.

Dual antiplatelet therapy (DAPT) is recommended for acute minor non-cardioembolic ischemic stroke, but the optimal P2Y12 inhibitor to combine with aspirin remains unclear. To characterize P2Y12 inhibitor selection and compare outcomes of clopidogrel- versus prasugrel-based DAPT in acute lacunar infarction. We retrospectively analyzed patients admitted within 24 h of symptom onset between January 2024 and December 2025 and treated with aspirin plus clopidogrel or prasugrel. We evaluated treatment selection, early neurological deterioration (END), in-hospital stroke recurrence, 3-month functional outcomes, and bleeding. Among 166 patients (73 clopidogrel, 93 prasugrel), prior antiplatelet therapy at stroke onset was independently associated with prasugrel selection. END occurred in 11% and 8% respectively, without a statistically significant difference. In-hospital stroke recurrence and 3-month functional outcomes did not differ significantly. Three mild lower gastrointestinal bleeding events occurred in the prasugrel group and none in the clopidogrel group. No statistically significant differences in the assessed outcomes were observed between groups; these findings do not establish equivalent efficacy or safety. Prior antiplatelet therapy at stroke onset was associated with prasugrel selection in routine practice.

PMID 43041980
阅读全文 →
PubMedEuropean journal of clinical pharmacology2026-11-17

Pharmacological strategies for hemodialysis arteriovenous fistula and graft patency: an access-stratified systematic review and network meta-analysis.

Shang Yiwei Y, Zheng Danna D, He Ran R, Luo Qikai Q et al.

Pharmacological therapies target different stages of hemodialysis access failure. We compared treatments separately in arteriovenous fistulas (AVFs) and grafts (AVGs), accounting for differences in outcomes and follow-up. This PROSPERO-registered review (CRD420261411441) followed PRISMA 2020 and PRISMA-NMA guidance. PubMed, Embase, CENTRAL/Cochrane records, and ClinicalTrials.gov were searched through May 31, 2026. Two reviewers independently screened records, extracted data, and assessed RoB 2. Separate random-effects frequentist network meta-analyses were supplemented by time-restricted analyses and exploratory follow-up meta-regression. Among 1,557 records, 31 reports were included; 23 trial datasets contributed to the primary analyses (15 AVF and 8 AVG). In AVFs, ticlopidine (OR, 0.37; 95% CI, 0.18-0.76) and clopidogrel (0.49; 0.24-0.97) may reduce predominantly early access failure (low certainty); estimates remained favorable at follow-up of 8 weeks or less. Larger single-trial effects for heparin plus anisodamine and clopidogrel plus a prostacyclin analog were very uncertain. Fish oil showed no clear AVF benefit. In AVGs, apixaban may reduce thrombosis (0.12; 0.03-0.41; low certainty), but its interval widened to 0.007-1.94 in the approximately 12-month subset. The aspirin estimate (3.35; 1.21-9.27) was very uncertain and imprecise under timing restrictions. Ticlopidine and clopidogrel may reduce early AVF failure without established improvement in functional maturation. AVG apixaban findings require confirmation, and the effect of aspirin remains very uncertain. Interpretation depends on the clinical outcome, follow-up, and bleeding risk.

PMID 43043490
阅读全文 →
PubMedArthroplasty today2026-11-16

Continuation of Clopidogrel in Total Knee Arthroplasty: Perioperative Bleeding and Cardiovascular Outcomes in a Consecutive Case Series.

Abbaszadeh Ahmad A, Mortazavi Seyed Mohammad Javad SMJ, Sahebi Mahdi M, Ayati Firoozabadi Mohammad M

Perioperative clopidogrel management in total knee arthroplasty (TKA) is challenging because interruption may increase thrombotic risk, whereas continuation may increase bleeding. Evidence remains limited. We retrospectively reviewed 31 consecutive patients (35 knees) undergoing primary TKA while continuing clopidogrel 75 mg daily (April 2018-September 2019). A multidisciplinary team involving orthopaedic surgery, cardiology, and anesthesiology determined continuation. One senior surgeon performed all procedures using a tourniquet-free technique with intravenous and intra-articular tranexamic acid. All patients also received low-dose aspirin for at least 2 weeks postoperatively as venous thromboembolism prophylaxis. Outcomes through 90 days included bleeding, transfusion, wound complications, infection, major adverse cardiac and cerebrovascular events, symptomatic venous thromboembolism, and anesthesia-related complications. Mean age was 69 ± 6.4 years; mean estimated blood loss was 285 ± 95 mL, and mean hemoglobin decrease was 1.8 ± 0.6 g/dL. No transfusions or major bleeding occurred. Minor wound drainage followed 3 procedures (8.6%), and superficial cellulitis occurred in 1 knee (2.9%); no deep infections occurred. Four patients (12.9%) reported mild, nonspecific headaches; none met criteria for post-dural puncture headache. No clinical signs or symptoms suggestive of spinal hematoma or persistent neurologic deficit, and no myocardial infarction, stroke, or cardiovascular death, were observed. Clopidogrel continuation during primary TKA may be feasible in carefully selected patients receiving multidisciplinary assessment and multimodal blood management. The small sample, retrospective design, and absence of a control group preclude conclusions about comparative safety.

PMID 43036796
阅读全文 →
PubMedBMC cardiovascular disorders2026-11-16

Comparison of methods to determine platelet reactivity under treatment with aspirin.

Rogozarski Jovan J, Kronberger Christina C, Skos Christof C, Schörgenhofer Christian C et al.

Insufficient response to aspirin is associated with increased cardiovascular risk, but its prognostic relevance in patients receiving potent P2Y12 inhibitors remains uncertain. We assessed methods to identify high on-treatment platelet reactivity (HTPR) under aspirin and evaluated the impact of potent versus less potent P2Y12 inhibition in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). Platelet function was analyzed in 757 aspirin-pretreated CAD patients treated with clopidogrel (n = 406), ticagrelor (n = 152), or prasugrel (n = 165). Antiplatelet efficacy was assessed using multiple electrode aggregometry (MEA), platelet function analyzer-100 (PFA-100®), cone and platelet analyzer (CPA), and serum thromboxane B2 (TXB2). All-cause mortality was assessed over five years, and major bleeding and major adverse cardiac events (MACE) over one year. AA-induced MEA > 6 U was associated with higher long-term mortality, however, discriminatory performance was modest (AUC = 0.575, p = 0.051), while CPA-SC < 6% strongly predicted major bleeding (AUC = 0.759, p = 0.001). None of the aspirin-related assays predicted MACE. Prasugrel or ticagrelor treatment was associated with lower long-term mortality than clopidogrel (HR = 0.411; 95% CI: 0.27-0.62; p < 0.001). Concomitant use of potent P2Y12 inhibitors and aspirin resulted in fewer aspirin semi- or non-responders and lower rates of dual HTPR. Dual HTPR occurred in ~ 1% of ticagrelor-, 2% of prasugrel-, and 7% of clopidogrel-treated patients. Exploratory analyses suggested that AA-MEA and CPA-SC were associated with long-term mortality and major bleeding, respectively. Given the modest discriminatory performance of AA-MEA, these findings require external validation. Potent P2Y12 inhibitors reduced dual HTPR, while platelet function assays provided complementary prognostic information in CAD.

PMID 43035652
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多clopidogrel napadisilate